Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism

Gunjan Dhawan1, Angela M Floden, Colin K Combs

  • 1Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58203, USA.

Neurobiology of Aging
|December 3, 2011
PubMed

Insights

Alzheimer's disease involves reactive microglia. Targeting microglial activation via tyrosine kinases with drugs like dasatinib may offer new Alzheimer's treatments.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is characterized by reactive microglia and amyloid-beta (Aβ) plaques.
  • Oligomeric Aβ (Aβ(o)) exacerbates neuroinflammation by activating microglia.

Purpose of the Study:

  • To investigate the role of tyrosine kinases in Aβ(o)-induced microglial activation.
  • To evaluate the therapeutic potential of the Src/Abl inhibitor dasatinib in Alzheimer's disease models.

Main Methods:

  • Primary murine microglia cultures and C57BL6/J mice were treated with Aβ(o).
  • Dasatinib was administered to assess its effect on microglial activation markers.
  • Human Alzheimer's disease brain tissue was analyzed for microglial changes.

Main Results:

  • Aβ(o) increased microglial protein phosphotyrosine and TNF-α levels.
  • Dasatinib significantly attenuated these increases in both cell cultures and mouse models.
  • Human AD brains showed increased microglial phosphotyrosine and phospho-Src levels associated with Aβ(o).

Conclusions:

  • Aβ(o) activates microglia through a tyrosine kinase-dependent pathway.
  • Dasatinib effectively reduces Aβ(o)-induced microglial inflammation.
  • Targeting tyrosine kinases represents a promising strategy for AD anti-inflammatory therapy.